23 completed. 23 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 23 |
| Phase 2 | 4 | Completed 4 |
Follow Olfactory Nerve Diseases: new trials by email Literature Review of Olfactory Nerve Diseases trials Research Report on Olfactory Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer HPPH, photodynamic therapy, conventional surgery - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Roswell Park Cancer Institute | 15 | 2006-10-19 | 2022-07-25 |
| Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Taxotere (Docetaxel), Alimta (Pemetrexed) - Breast Cancer, Esophageal Cancer | Phase 1 | Completed | University of Arizona | 33 | 2005-09-01 | 2015-12-03 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| NGR-TNF in Treating Patients With Advanced Solid Tumors CNGRC peptide-TNF alpha conjugate - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 70 | 2004-09-01 | 2012-09-24 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-07-01 | 2013-04-10 |
| Thalidomide and Docetaxel in Treating Patients With Advanced Cancer docetaxel, thalidomide - Cancer | Phase 1 | Completed | Case Comprehensive Cancer Center | 26 | 2002-07-01 | 2010-06-11 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction erlotinib hydrochloride, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 2001-12-01 | 2013-01-16 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2001-12-01 | 2013-09-30 |
| Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor capecitabine, carboplatin, epirubicin hydrochloride - Esophageal Cancer, Extrahepatic Bile Duct Cancer | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 2001-07-01 | 2012-03-08 | |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer vorinostat - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2001-07-01 | 2013-05-30 | |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer hydroxyurea, fluorouracil, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2001-07-01 | 2013-02-07 |
| MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma entinostat - Cancer | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 75 | 2001-03-01 | 2012-03-15 |
| Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors capecitabine, cisplatin - Cancer | Phase 1 | Completed | NYU Langone Health | 2000-08-01 | 2011-04-05 | |
| SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck paclitaxel, semaxanib - Head and Neck Cancer | Phase 1 | Completed | Case Comprehensive Cancer Center | 12 | 2000-05-01 | 2010-06-10 |
| Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors cisplatin, lurtotecan liposome - Head and Neck Cancer, Lung Cancer | Phase 1 | Completed | NCIC Clinical Trials Group | 14 | 2000-03-22 | 2020-04-06 |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors filgrastim, docetaxel, gemcitabine hydrochloride - Bladder Cancer, Breast Cancer | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 35 | 2000-03-01 | 2013-08-28 |
| Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer tanespimycin - Bladder Cancer, Breast Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 1999-07-01 | 2013-06-24 |
Showing 20 of 23. Sign in to see all of them.
Esthesioneuroblastoma, Olfactory (23) · Squamous Cell Carcinoma of Head and Neck (21) · Salivary Gland Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (15) · Breast Neoplasms (13) · Colonic Neoplasms (12) · Carcinoma, Ovarian Epithelial (11) · Esophageal Neoplasms (11) · Head and Neck Neoplasms (10) · Stomach Neoplasms (10) · Carcinoma, Renal Cell (9) · Pancreatic Neoplasms (9) · Prostatic Neoplasms (9) · Rectal Neoplasms (8) · Breast Neoplasms, Male (7)
Carcinoma (23) · Cranial Nerve Diseases (23) · Neoplasms by Histologic Type (23) · Neoplasms by Site (23) · Neoplasms, Germ Cell and Embryonal (23) · Neoplasms, Glandular and Epithelial (23) · Neoplasms, Nerve Tissue (23) · Neoplasms, Neuroepithelial (23) · Nervous System Diseases (23) · Neuroectodermal Tumors (23) · Neuroblastoma (22) · Stomatognathic Diseases (22) · Carcinoma, Squamous Cell (21) · Mouth Diseases (20)
Docetaxel (5) · Cetuximab (3) · Erlotinib Hydrochloride (3) · Bevacizumab (2) · Capecitabine (2) · Cisplatin (2) · Filgrastim (2) · 1-phenyl-3,3-dimethyltriazene (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (1) · 7-hydroxystaurosporine (1) · Carboplatin (1) · Congresses as Topic (1) · E6 protein, Human papillomavirus type 16 (1) · Epirubicin (1)
National Cancer Institute (NCI) (7) · Memorial Sloan Kettering Cancer Center (3) · Case Comprehensive Cancer Center (2) · National Institutes of Health Clinical Center (CC) (2) · City of Hope Medical Center (1) · Dartmouth-Hitchcock Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fox Chase Cancer Center (1) · NCIC Clinical Trials Group (1) · NYU Langone Health (1) · Roswell Park Cancer Institute (1) · Sanjiv Sam Gambhir (1) · University of Arizona (1)
United States (21) · Canada (1) · Germany (1) · Netherlands (1)
Scot C. Remick, MD (2) · Alain Mita (1) · Antonius Miller (1) · Barbara Burtness (1) · Barry L. Gause, MD (1) · Brian P. Monahan, MD, FACP (1) · Cornelis J. A. Punt, MD, PhD (1) · David Solit (1) · Eva Szabo, MD (1) · Everett Vokes (1) · Franco M. Muggia, MD (1) · Hal W. Hirte, MD, FRCP(C) (1) · Hassan Arshad (1) · Howard I. Scher, MD (1) · James H. Doroshow, MD (1)
PMID 15033677, PMID 18470481, PMID 20145168, PMID 20407240, PMID 23868427, PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872
P30CA043703 (2), P30CA016087 (1), P30CA023074 (1), P30CA023108 (1), P30CA033572 (1), P30CA044579 (1), P30CA054174 (1), P30CA068485 (1), U01CA062502 (1), U01CA062505 (1), U01CA069853 (1), U01CA069856 (1), U10CA031946 (1)